Metformin Enhances Anti-proliferative Effect of Cisplatin in Cervical Cancer Cell Line  

Oleh:

Yudhani, Ratih D. ; Pesik, Riza N. ; Indarto, Dono

Jenis: Article from Journal - ilmiah nasional - terakreditasi DIKTI
Dalam koleksi: Jurnal Farmasi Klinik Indonesia (Indonesian Journal of Clinical Pharmacy) vol. 5 no. 2 (Jun. 2016), page 75-83.
Topik: Anti-proliferative effect; combination index; cervical cancer; cisplatin; metformin
Fulltext: 1. juni 2016 ijcp-1201145.pdf (465.33KB)

Isi artikel

Cervival cancer is one of the top rank of gynecological malignancy in the world, leading to high morbidity and mortality rates. Cisplatin is a chemotherapeutic agent that is generally used to treat cervical cancer but the use of this drug is limited because of serious side effects. Metformin, a diabetic drug, decreases not only blood glucose levels but also cell viability of some cancer cells. The aim of this study was to investigate the anti-proliferative effect of combination metformin and cisplatin in HeLa cells (cervical cancer cell line). Anti-proliferative effect of these combined drugs was analized using MTT assay, combination index assay and HeLa cell morphology. Inhibitory concentration (IC50) of cisplatin and metformin was determined before performing combination index assay. Administration of 10 mM metformin showed inhibition of HeLa cell proliferation and it reached 50% inhibition of cell proliferation at 60 mM. Whilst, cisplatin showed a stronger anti-proliferative effect with initial inhibition dose at 12 µM and IC50 dose at 44 µM. Combination of 30 mM metformin and 5 µM cisplatin indicated the strongest anti-proliferative effect on HeLa cell. In conclusion, metformin may become a promising drug for treatment of cervical cancer in future which enhances anti-proliferative effect of cisplatin.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali